Cite
SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
MLA
Liu, Ju-E., et al. “SLCO1B1 521T > C Polymorphism Associated with Rosuvastatin-Induced Myotoxicity in Chinese Coronary Artery Disease Patients: A Nested Case-Control Study.” European Journal of Clinical Pharmacology, vol. 73, no. 11, Nov. 2017, pp. 1409–16. EBSCOhost, https://doi.org/10.1007/s00228-017-2318-z.
APA
Liu, J.-E., Liu, X.-Y., Chen, S., Zhang, Y., Cai, L.-Y., Yang, M., Lai, W.-H., Ren, B., & Zhong, S.-L. (2017). SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. European Journal of Clinical Pharmacology, 73(11), 1409–1416. https://doi.org/10.1007/s00228-017-2318-z
Chicago
Liu, Ju-E, Xiao-Ying Liu, Sheng Chen, Yan Zhang, Li-Yun Cai, Min Yang, Wei-Hua Lai, Bin Ren, and Shi-Long Zhong. 2017. “SLCO1B1 521T > C Polymorphism Associated with Rosuvastatin-Induced Myotoxicity in Chinese Coronary Artery Disease Patients: A Nested Case-Control Study.” European Journal of Clinical Pharmacology 73 (11): 1409–16. doi:10.1007/s00228-017-2318-z.